Better feasibility of rapid test kits for infectious diseases can be achieved by improving the analytical sensitivity of the test kits in order to detect maximal amount of the infected individuals. With a combination of engineered binder molecules, traditional LFA-membranes and highly detectable reporter particles, the analytical sensitivity of the tests can be improved to match the tests currently done in centralized laboratories. These high-performance rapid test-kits can potentially broaden the selection of infectious diseases that can be tested in near-patient conditions. The project aims to produce - i) an easily operated and reliable multiplex assays with plastic cassettes for the mentioned analytes (HIV, HCV and HBV); ii) incorporate up-converting nanoparticle (UCP) reporter technology in the produced assays to achieve maximal assay sensitivity and; iii) produce affordable mass-producible reader device to measure and interpret assay signals to interpret test results. Dr Gaurav Batra of The Translational Health Science & Technology Institute (THSTI) leads a collaboration involving The International Centre for Genetics Engineering & Biotechnology (ICGEB), University of Turku, Kaivaogen, and Designinnova. The team aims to produce a new technology concept which upgrades the performance of the currently used rapid-testing methodology with lateral flow assay (LFA) test kits. The goal is to test infectious diseases including HIV, HBV and HCV in near-patient conditions with high accuracy and reliability without sacrificing the affordability of the testing.